PDCD1 and colorectal carcinoma: In 2017, the U.S. Food and Drug Administration (FDA) approved the PD-1 antibodies pembrolizumab and nivolumab for the second-line treatment of CRC patients with deficient DNA mismatch repair/microsatellite instability-high (dMMR/MSI-H) (3).